MetrioPharm AG focuses on the further development, regulatory approval and marketing of successfully tested, innovative medicine.

The active ingredients of class MP 1000 were developed by well-known scientists in Russia. But the inventors lacked of know-how about international regulatory approval, funds and knowledge of the pharmaceutical market. So they could not get their benefit of cooperations and license contracts with large pharmaceutical enterprises in the USA, Europe and Japan.

MetrioPharm AG was set up to bring the outstanding pharmaceutical developments of the MP 1000-products to a powerful and growing business, using our knowledge in pharmaceutical development, international approval and licensing and our ability to raise funds.

MetrioPharm AG's aim is to continue the development of MP 1000 active ingridients within the next two to three years. As a result the licenses of several therapeutical active ingridients will be sold to international pharmaceutical companies. These established pharmaceutical companies will ensure a fast approval and a wide spread marketing approach of the MP 1000-based ingridients. MetrioPharm AG's target profit will be accomplished by single payments and tracking of licensing fees.

Therewith MetrioPharm AG concentrates on a segment of biotech-development which allows a high increase of value at comparatively low costs and restricted risks.